Key result
Ultrasound screening for NAFLD is proposed to guide cardiovascular risk reduction in type 2 diabetes.
We read with great interest the recent article by Targher et al. (1) reporting the prevalence of nonalcoholic fatty liver disease (NAFLD) and associated cardiovascular disease (CVD) risk factors in patients with type 2 diabetes. Proper identification of patients with NAFLD is of major importance for adequate treatment and reduction of CVD risk in type 2 diabetic patients. However, routine ultrasound examination of the abdomen for the screening of hepatic steatosis in combination with serologic …
No takes yet. Share an insight, caveat, or question.
Schindhelm et al. (2007) conducted a letter in Nonalcoholic fatty liver disease and cardiovascular disease in type 2 diabetes. Routine abdominal ultrasound screening for hepatic steatosis was evaluated. Identification of nonalcoholic fatty liver disease via abdominal ultrasound screening is discussed for cardiovascular risk reduction in type 2 diabetes (no quantitative data reported in this letter).
Synapse has enriched 5 related papers. Consider them for comparative context: